Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...

The FDA accepts and grants priority review to BAYRY's sNDA for Kerendia to treat patients with a common form of heart failure ...

The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s (BAYN: DE) supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone ...

Healthcare companies rose as traders sought out sectors that are less vulnerable to swings in economic growth and inflation prospects.

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...

Berlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug ...

Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.

Avado, a leading provider of professional learning, is introducing CIPD Level 5 Plus ? a premium offering for those pursuing their CIPD qualification. Building on the success of Avado's existing CIPD ...

OneSpot, an insurance billing software company for eyecare practices, announced today that it now supports Eye Cloud Pro, a cloud-based EHR in the eyecare industry. OneSpot is productivity software ...

Pharmaceuticals grew by 2.4%, with new drugs Nubeqa (prostate cancer) and Kerendia (metabolic disease) posting strong adjusted growth of 73% and 62%, respectively, but partially offset by ...

The pharmaceuticals division exceeded expectations with significant growth in flagship products NUBEQA and KERENDIA, reaching EUR 2 billion in sales. The company successfully reduced its net debt ...

The pharmaceuticals division exceeded expectations with significant growth in flagship products NUBEQA and KERENDIA, reaching EUR 2 billion in sales. The company successfully reduced its net debt to ...